JNJ is well positioned for an interesting 2021 as COVID vaccine is a driver of growth and rebound in its Medical Devices Division should propel the stock price to new highs. Unlike the vaccines from Pfizer (PFE) and Moderna (MRNA), Johnson & Jonson's vaccine only calls for one dose in the treatment regimen. This stock offers worthwhile risk-adjusted, total return potential with a dividend yeld of 2.80%